Stock Pulse
Intuitive Surgical (ISRG) saw positive developments with FDA clearance for its SureForm 45 stapler, enhancing the da Vinci SP system's capabilities [3], [5]. Q4 2024 results were strong, with a 25% revenue increase and a 17% rise in procedures performed [1]. The company is highlighted as a top medical stock pick by billionaires [1] and for its strong performance and future potential, with projected revenue growth of around 15% [6]. While a recent market rally boosted the stock price [4], the upcoming earnings report will be crucial for sustained growth [4], [9]. Despite positive momentum, potential risks include a high P/E ratio and a "Hold" rating from Zacks [9], [10]. However, continuous innovation like the new stapler and force feedback technology [2], combined with a strong market position [1], [7], represent significant opportunities.